Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon Drug Discovery - Chemistry Department

Page View:

   The Efficient Chemistry Team Delivering on Time

The Medicilon Chemistry Department is a professional, efficient, and well-qualified R&D team. The team has more than 40% of employees with a master's degree, doctor's degree, or above. Dr. Ma Xingquan, vice president of the chemistry department, graduated from the famous State Key Laboratory of Life and Organic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. , the National Institutes of Health), and an associate researcher at the world's top authoritative academic institution Scripps Research Institute (TSRI, The Scripps Research Institute), on the frontier fields of sugar chemistry, phospholipid chemistry, and polyphenol chemical biology. He has conducted in-depth research in other areas. He has published more than 20 academic papers in domestic and foreign core journals, including JACS, ANEW, LANGMUIR, OBC, JMCL, etc. At the same time, he has conducted in-depth research on ADC drug R&D and technology development, PROTAC technology development and drug research. He has accumulated rich knowledge and experience in drug R&D.

This efficient chemistry research team has proud performance parameters:

    FFS on-time delivery rate > 80%;
    Chemical reaction success rate > 85%;
    FTE delivers about 1 compound per person per week;
    > 10 reactions completed per researcher per week;

The Medicilon Chemistry Department races against time in dealing with customers' projects, and the mission must be achieved. The tasks must be delivered efficiently and on time to be satisfied and trusted by customers.

In 2019 and early 2020, the Chemistry Department will successively settle in the 10,000-square-meter laboratory in Nanhui Park.

Medicilon Nanhui Park.webp

 Nanhui Park- 10,000 Square Meters With a New Look

In 2019 and early 2020, the Chemistry Department will successively settle in the 10,000-square-meter laboratory in the Southwest Park of Medicare. The brand-new laboratory, complete equipment and facilities, and modern process management all guarantee the project's high-quality progress.

The Medicilon Chemistry Department is well-equipped, and the primary instruments include UPLC, HPLC, LC-MS, GC-MS, GC, IC, SFC, prep-HPLC, MS directed Prep-HPLC, LC-MS-MS and other chromatographic analyzers, Biotag microwave reactor, high configuration semi-auto-chromatography system, Lyophilyzer, differential scanning calorimeter (DSC), thermogravimetric analyzer (TGA), X-ray powder diffraction (XRPD), particle size analyzer (PSD), polarized light Microscope (Polarized light microscopy), Nuclear Magnetic Resonance (NMR), Fourier Transform Infrared Spectroscopy (FT-IR), Moisture Analyzer (KF), Ultraviolet and Visible Spectroscopy (UV-Vis), Polarimeter, ICP- MS and so on. See more about Analytical Chemistry Services.

Medicilon Chemical Division Instruments.webp

  At the Forefront of Innovation: PROTAC

The Medicilon Chemistry Department is at the forefront of innovative drug research and development. The scientific research team has established the PROTAC drug discovery technology platform, which summarizes the current popular target protein ligands and establishes a wide range of popular target protein high-affinity small molecules and small molecule fragments. The compound library (TPSM), a wide range of E3 ligase high-affinity small molecules and small molecule fragments (E3SM), established a linker system, including an extensive collection of bifunctional linkers (BF-Linker) with a wide range of diversity. These accumulated compound libraries can help quickly and efficiently synthesize many highly active PTROTAC bispecific small molecules, significantly improving the drug development process using PROTAC technology. In addition to rapid synthesis, we also established and improved the PROTAC biological screening and testing platform and developed it to all preclinical stages. We aim to establish a technology platform that can simultaneously undertake 10 to 20 PROTAC R&D projects and help generate 10 to 20 PROTAC drug candidates annually.

This technology platform has established PROTAC technical services with several biopharmaceutical companies, and some projects have advanced to the preclinical research stage. Medicilon Chemistry Department can further undertake a large number of PROTAC-related businesses.

PROTAC Technology.webp

  Customer recognition from well-known pharmaceutical companies

The Medicilon Chemistry Department cooperates with well-known pharmaceutical companies at home and abroad to complete custom synthesis, compound library construction, target compound screening, compound structure and function optimization, and other aspects of multi-dimensional business cooperation. Cooperated customers include GSK, ROCHE, J&J, Genentech, Biogen, GILEAD, Takeda, Hengrui, Simcere Pharmaceuticals, Jimin Trusty, Chia Tai Tianqing Pharmaceuticals, etc.

Adhering to "focusing on innovation and serving with heart," Medicilon has always regarded every customer as the company's VIP, choosing efficient and high-quality methods to carry out customers' scientific research projects, actively communicating, and reporting on time, unanimously recognized by customers. Dr. Ma Xingquan often said that a CRO company is service-oriented, and the customer is God. We sincerely look forward to cooperating with you and sincerely thank you for your support and help!

Adhering to the concept of "Focus on innovation and serve with heart," Medicilon has always regarded every customer as the VIP of the company.

Medicilon's chemistry services coopration.webp

Medicilon can undertake the synthesis of special reagents, intermediates and molecular fragments, preparation of standard products, synthesis design and preparation of impurities or metabolites, synthesis of stable isotope internal standards and synthesis of tritiated compounds.

Related Articles:

Aim at chemical synthesis through Ibuprofen

Medicilon FTE services & FFS services - flexible and efficient cooperation model

Medicilon Drug Discovery--Opening the Door of Innovative Drugs with Science and Professionalism

 About Medicilon

Medicilon (stock code: 688202) is a drug research and development outsourcing service company (CRO). Founded on February 2, 2004, the company has gone through 16 years. It has established a collection of compound synthesis, compound activity screening, structural biology, pharmacodynamic evaluation, pharmacokinetic evaluation, toxicology evaluation, and preparation research in Shanghai. A comprehensive technical service platform that meets international standards, is integrated with new drug registration, and has been recognized by international drug management departments. Medicipia's animal experiment facilities have been certified by AAALAC (Association for Animal Assessment and Accreditation International) and the NMPA GLP certificate of the National Medical Products Administration. They have reached the GLP standards of the US Food and Drug Administration.

Medicilon has rich experience in global cooperation. Since 2015, Medicilon has served more than 500 active customers worldwide and provided services to many international pharmaceutical companies such as Takeda Pharmaceutical, Johnson & Johnson, GlaxoSmithKline, and Roche Pharmaceuticals. Well-known domestic and foreign customers such as Swiss Medicine, Yangzijiang Pharmaceutical, CSPC, Huahai Pharmaceutical, and Zhongsheng Pharmaceutical provide R&D outsourcing services.

Contact us


Relevant newsRelevant news